Masahiro Utoh

TL;DR: Capecitabine is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil preferentially in tumors, which is explained to a great extent by the activity of TP in colorectal tumor tissue, (the enzyme responsible for the conversion of 5′-DFUR to 5-FU), which is approximately four times that in adjacent healthy tissue.

TL;DR: Compared the efficacy of capecitabine and 5-FUra at their maximum tolerated doses in CXF280, HCT116, COLO205, and WiDr human colon cancer xenograft models, and measured subsequent 5'-FUra and 5'-dFUrd levels in tumors and in the plasma and muscle, cape citabine might show its high efficacy as a result of delivering high levels of 5'FUra selectively to the tumors.

TL;DR: It is recommended that capecitabine be administered with food as this procedure was used in the clinical trials, and a profound influence on Cmax of cape citabine and most of its metabolites was found.

TL;DR: Mild to moderate hepatic dysfunction had no clinically significant influence on the pharmacokinetic parameters of capecitabine and its metabolites, and there is no need for, a priori, adjustment of the dose.

TL;DR: The effect of concomitantly delivered Maalox on the extent and rate of gastrointestinal absorption of cape citabine is not clinically significant and there is no need to adjust the dose or timing of capecitabine administration in patients treated with Maal Ox.